RenovoRx To Announce Promising New Clinical Data Using its TAMP™ Therapy Platform in an Abstract to be Presented at ASCO GI 2026

Core Insights - New pharmacokinetic (PK) and pharmacodynamic data from a sub-study in the Phase III TIGeR-PaC trial supports the efficacy of RenovoRx's TAMP therapy platform for targeted drug delivery in treating locally advanced pancreatic cancer (LAPC) [1][2][4] Group 1: Clinical Data and Findings - The sub-study evaluated intra-arterial gemcitabine (IAG) using the TAMP platform, showing reduced systemic levels of gemcitabine and increased levels of its inactive metabolite compared to intravenous (IV) gemcitabine [3][5] - A direct correlation was found between increased metabolite levels and reduced CA 19-9, a biomarker for chemotherapy response, indicating potential for improved clinical outcomes [3][4] - The study involved 16 patients across six clinical sites, with 11 receiving TAMP and IAG, and five receiving IV gemcitabine, measuring systemic drug exposure and peak plasma concentrations [5] Group 2: Implications for Treatment - The findings suggest that TAMP and IAG may enhance local drug potency while minimizing side effects associated with standard chemotherapy, providing a transformative option for LAPC patients [4][9] - The TAMP therapy platform aims to deliver chemotherapy directly to the tumor site, potentially improving treatment efficiency and effectiveness [4][9] Group 3: Company Overview and Future Directions - RenovoRx is focused on developing targeted oncology therapies and has commercialized the RenovoCath device, which is FDA-cleared for drug delivery [9][10] - The company is actively commercializing its TAMP technology and has generated approximately $900,000 in revenue from RenovoCath sales in the first nine months of 2025 [10] - RenovoRx is also exploring further revenue-generating activities and expanding its customer base among high-volume cancer centers [10]